Acurx's Ibezapolstat Shows Microbiome Preservation Potential in Recurrent C. difficile Infections — Acurx Pharmaceuticals, Inc.

Event summary

Acurx presented microbiome preservation data for ibezapolstat at the Anaerobe Society of the Americas Congress on July 8-10, 2026.
Study showed beneficial gut microbes persist despite prior vancomycin/fidaxomicin treatments in multiply-recurrent CDI patients.
Ibezapolstat outperformed comparators in biofilm killing effects without causing VRE overgrowth.
Company plans to initiate a 20-patient pilot trial for multiply-recurrent CDI in Q4 2026.

The big picture

Acurx's data suggests ibezapolstat could address the significant unmet need in preventing recurrent C. difficile infections, potentially shifting treatment paradigms. The company is well-positioned with regulatory alignment from both FDA and EMA as it prepares for Phase 3 trials. With recurrent CDI representing a $2.8 billion annual cost burden in the U.S., successful development of ibezapolstat could capture substantial market share.

What we're watching

Clinical Trial Execution: Whether the upcoming pilot trial will demonstrate ibezapolstat's efficacy in multiply-recurrent CDI patients and inform Phase 3 design.
Regulatory Strategy: How Acurx will leverage FDA's Limited Population Pathway for potential approval of both treatment and prevention of recurrent CDI.
Market Differentiation: The pace at which ibezapolstat can establish itself as a single-agent solution compared to current two-drug regimens for recurrent CDI.